Johnson & Johnson (JNJ) Stock Analysis
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $228.69, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth.
Johnson & Johnson researches, manufactures, and sells healthcare products through two segments: Innovative Medicine (oncology, immunology, neuroscience, pulmonary hypertension, HIV, cardiovascular) and MedTech. Employs approximately 138,200 people worldwide; approximately 43% of... Read more
Hold if already holding. Not a fresh buy at $228.69, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.2/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, earnings proximity 75d clear, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and news soft fda negative. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $228.69, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $239.32 (+4.6%), stop $219.16 (−4.3%), A.R:R -0.1:1. Score 5.2/10, moderate confidence.
Take-profit target: $239.32 (+4.6% upside). Target $239.32 (+4.6%), stop $219.16 (−4.3%), A.R:R -0.1:1. Stop-loss: $219.16.
Analyst target reached - limited upside remaining; Weak growth.
Johnson & Johnson trades at a P/E of 26.7 (forward 18.1). TrendMatrix value score: 4.7/10. Verdict: Hold.
32 analysts cover JNJ with a consensus score of 3.8/5. Average price target: $252.
What does Johnson & Johnson do?Johnson & Johnson researches, manufactures, and sells healthcare products through two segments: Innovative Medicine...
Johnson & Johnson researches, manufactures, and sells healthcare products through two segments: Innovative Medicine (oncology, immunology, neuroscience, pulmonary hypertension, HIV, cardiovascular) and MedTech. Employs approximately 138,200 people worldwide; approximately 43% of 2025 sales occurred outside the U.S., with ~23% in Europe and 15% in Asia-Pacific and Africa.